Recent Advances in Therapeutic Cancer Vaccines and their Outcomes

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 87

Special Issue Editors

UICentre for Drug Discovery, College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA
Interests: cancer chemoprevention; tumor immunology; innate immunology of diabetic wounds; immunotoxicity; adjuvants
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Surgery, Division of Surgical Oncology, University of Illinois Chicago, Chicago, IL 60612, USA
Interests: cancer therapeutics and cancer immunology; innate immunity; cerebral malaria
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccine targets are selected based on several factors, including the tumor microenvironment, which plays an important role in the clinical outcome. Immunotherapies that engage both the adaptive and innate immune systems have the potential to enhance cancer therapeutics. This Special Issue will focus on recent advances in therapeutic cancer vaccines and their outcomes. Specifically, we will look at how the antigen repertoire for vaccine targets can be improved and expanded, consider new developments in vaccine platforms, and explore in situ vaccines. The Special Issue will explore the identification of biomarkers for cancer prognosis and evaluate the mechanism of action and adverse effects associated with antigen targeting. Other potential topics include:

  • Combining vaccine platforms with novel immunomodulatory approaches;
  • Treatments for overcoming tumor resistance and enhancing clinical efficacy;
  • Adoptive transfer therapy and Chimeric Antigen Receptor (CAR) T-cell therapy;
  • Vaccine-related therapies and immune checkpoint inhibitors;
  • Future perspectives on cancer vaccines.

Dr. Ruchi Roy
Dr. Sunil Singh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer therapeutics
  • vaccines
  • cancer biomarkers
  • prognosis

Published Papers

This special issue is now open for submission.
Back to TopTop